Outlook Therapeutics, Inc. 8-K

What Happened
On February 18, 2026, Outlook Therapeutics, Inc. announced it received a notice from the Nasdaq Listing Qualifications Staff that its common stock has closed below the $1.00 minimum bid price required by Nasdaq Listing Rule 5550(a)(2) for the last 30 consecutive business days. The notice does not immediately affect the listing; the company has 180 calendar days (until August 17, 2026) to regain compliance.

Key Details

• Notice date: February 18, 2026; deficiency: closing bid price below $1.00 for 30 consecutive business days.
• Compliance deadline: 180 calendar days from notice, i.e., August 17, 2026; to cure, the stock must close at $1.00+ for at least 10 consecutive business days before that date.
• Possible extension: the company may be eligible for an additional 180-day compliance period if it meets Nasdaq’s market value of publicly held shares and other initial listing standards (except the bid-price rule) and notifies Nasdaq—often addressed via a reverse stock split if needed.
• If compliance is not achieved and Nasdaq moves to delist, Outlook can appeal the determination to a Nasdaq hearings panel, but success is not assured.

Why It Matters
A continued failure to meet Nasdaq’s $1.00 bid-price requirement could lead to delisting, which can reduce liquidity, limit investor access, and negatively affect the stock price. The company says it will monitor the closing bid price and evaluate options to regain compliance; investors should watch the bid price and any actions (such as a reverse stock split) or announcements that Outlook Therapeutics makes before the August 17, 2026 compliance deadline.